Drug intelligence / Profile preview

RioDerm002

Development stage: Unknown
Lead developer: RION
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Topical

Overview

RioDerm002 (also known as RioDerm-002) is a biologic therapeutic candidate under development by Rion for the treatment of radiation-induced tissue injury and wounds. It is based on the company's proprietary Purified Exosome Product (PEP) technology, which utilizes platelet-derived exosomes. These extracellular vesicles are enriched with thrombin and other regenerative factors to promote wound healing and tissue repair. The drug is currently in Phase I clinical development, specifically targeting radiation injury.

Other names: RioDerm-002RioDerm002RioDerm 002

Targets

F2 (Thrombin)

Beyond the preview

Go deeper on RioDerm002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RioDerm002.

Explore the full profile